TickerFacts.

Zymeworks Inc. (ZYME): Revenue

Annual figures by period end, from SEC filings.

$105.97M
Year ended 2025-12-31
$37.13M
Trailing 12 months to 2026-06-30
-36.4%
3-year compound annual growth
+22.2%
5-year compound annual growth
$412.48M2020-12-31: $38.95M2021-12-31: $26.68M2022-12-31: $412.48M2023-12-31: $76.01M2024-12-31: $76.30M2025-12-31: $105.97M$105.97M
2020-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$105.97M+38.9%2026-03-02, From 2025-01-01
2024-12-31$76.30M+0.4%2026-03-02, From 2024-01-01
2023-12-31$76.01M-81.6%2026-03-02, From 2023-01-01
2022-12-31$412.48Mn/m2025-03-05, From 2022-01-01
2021-12-31$26.68M-31.5%2024-03-06, From 2021-01-01
2020-12-31$38.95Mn/a2023-03-07, From 2020-01-01

Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Zymeworks Inc. (ZYME)2025-12-31$105.97M+38.9%
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$106.47M+350.9%
UroGen Pharma Ltd. (URGN)2025-12-31$109.79M+21.4%
Gyre Therapeutics, Inc. (GYRE)2025-12-31$116.59M+10.2%
Siga Technologies Inc (SIGA)2025-12-31$94.57M-31.8%
Xencor Inc (XNCR)2025-12-31$125.58M+13.7%
Cytokinetics Inc (CYTK)2025-12-31$88.04M+376.6%
Lifecore Biomedical, Inc. (LFCR)2025-05-25$128.87M+0.5%
Standard Biotools Inc. (LAB)2025-12-31$85.33M-6.2%

Compare ZYME, ZVRA, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗